Phase A — Understand the business
Lens 1 · Company Overview
Natera is a molecular diagnostics company built on a single platform — cell-free DNA (cfDNA) sequencing married to proprietary bioinformatics/statistical algorithms — pointed at three end-markets: oncology, women's health, and organ health. It reports as one operating segment (molecular testing services), with the CEO as CODM.
The business is, in plain terms, a lab-services razor-and-razor model with a reimbursement engine bolted on: Natera runs blood/tissue samples through its CLIA labs (Austin TX, San Carlos CA; Boulder CO for trials), delivers a result, and bills insurers, Medicare, patients, clinics, or lab-distribution partners. Revenue is recognized per reported unit (a test delivered with a result) under ASC 606, using expected-value estimation of variable consideration — i.e., Natera books revenue at the cash it expects to collect, not list price, because payer reimbursement is the binding constraint.
Key products:
- Signatera — personalized, tumor-informed ctDNA test for molecular residual disease (MRD): recurrence monitoring, treatment-response, immunotherapy response. The growth engine.
- Panorama — non-invasive prenatal test (NIPT) for chromosomal abnormalities. Legacy volume base; available in the US + Europe.
- Horizon — hereditary carrier screening.
- Prospera — organ-transplant rejection assessment (kidney/heart/lung).
- Adjacencies: Latitude (tissue-free CRC MRD), Altera (comprehensive genomic profiling), Empower (hereditary cancer), Fetal Focus/Vistara/Anora (women's health), and Constellation — a cloud/licensing model where partner labs run the wet work and pay to access Natera's algorithms (lower revenue/test, lower cost/test).
Customers/channel: ~96% of revenue runs through Natera's own US direct sales force; ~3% US lab-distribution partners; ~1-2% international. The majority of revenue comes from in-network insurer contracts. No single customer exceeds 10% of revenue; ~14.8% of total revenue is paid by traditional Medicare on behalf of multiple customers. Concentration is therefore in the payer mix (Medicare + a handful of large commercial payers), not in any one buyer.
Key supplier: Illumina — Natera filed the "Eleventh Amendment to Supply Agreement, dated March 2, 2026, by and between the Registrant and Illumina, Inc." as Exhibit 10.1 to the Q1 10-Q. Sequencing reagents/instruments are a single-vendor dependency (see Lens 2).
Lens 2 · Supply Chain
Upstream → Natera → end payer/patient, with named stakeholders:
- Sequencing inputs (the chokepoint): Illumina sequencers + reagents. The 11th amendment to the supply agreement (Mar 2026) signals an ongoing, deepening single-source relationship; the 10-Q's contractual-commitments table shows $136.1M committed to "material suppliers" through Nov 2030 and $16.2M to a "laboratory instruments supplier" through Dec 2027. This is the classic genomics chokepoint — every cfDNA shop (Guardant, Exact, Veracyte, CareDx) sits behind Illumina (or, increasingly, an Illumina/Element/Ultima split). A reagent price hike or allocation event hits Natera's COGS directly.
- Other named commitments: application-service providers $16.4M (to Feb 2034), a cloud-platform provider $20.2M (to Mar 2029 — the Constellation/compute backbone), "other material suppliers" $72.4M. Total contractual commitments $261.4M.
- The labs: Austin TX + San Carlos CA (clinical), Boulder CO (trials, acquired via Foresight). A portion of testing is outsourced to third-party labs.
- Sample acquisition for R&D: Natera buys clinical samples + data for oncology development — paid $15.0M to date with up to $50.0M more contingent on approvals/volume. The data moat is partly bought.
- Downstream: insurers (commercial + traditional Medicare ~15% of rev), patients, clinics, pharma partners (clinical-trial testing), and Constellation lab-licensees.
Chokepoint verdict: the binding external dependency is Illumina sequencing supply; the binding internal dependency is payer reimbursement coverage (Medicare LCDs + commercial contracts), which is really a regulatory/commercial chokepoint, not a physical one. Single-source on the wet side, concentrated-payer on the cash side.
Lens 3 · Competitive Advantages (moats)
Natera's moat is not the sequencer (commodity, rented from Illumina). It is three compounding assets:
- Reimbursement estate + Medicare coverage breadth. This is the real moat in lab diagnostics. Signatera carries CMS ADLT status (Advanced Diagnostic Laboratory Test) with a fee that entered at $3,500/assay and rose as high as ~$3,920 for CY2025. Signatera holds Medicare coverage across colorectal, breast, ovarian, bladder, lung (surveillance), and pan-cancer immunotherapy monitoring under LCD L38779. Each new covered indication is a one-way ratchet that competitors must re-clear independently — coverage is earned per-indication, per-payer, over years.
- Tumor-informed data + IP estate. Signatera is bespoke (built from each patient's tumor), which historically out-sensitised tumor-naïve assays. The IP is litigated aggressively (Lens 10/13) — Natera has won injunctions (NeoGenomics RaDaR pulled from market; a 30% ongoing royalty imposed on ArcherDX/Invitae's PCM) but has also seen patents invalidated. The Foresight Diagnostics acquisition ($424.5M, Dec 2025) bought PhasED-Seq phased-variant IP to push sensitivity further.
- Scale + clinical-evidence flywheel. ~3.5M tests/yr processed in FY2025; a deep trial portfolio (ALTAIR, BESPOKE, SINERGY, CALGB/SWOG 80702) generates the peer-reviewed evidence that drives the next coverage decision. Evidence → coverage → volume → more evidence.
Bargaining power: weak vs. Illumina (single-source upstream); weak-to-moderate vs. large payers (they set reimbursement, and going in-network lowers realized price — management says so explicitly); strong vs. patients/clinicians once a test is standard-of-care and covered. The moat is durable but regulatory, not structural — it can be eroded by a payer policy change or a competitor clearing the same LCD.
Lens 4 · Segments
Natera reports one GAAP segment and does not disclose revenue by oncology/women's-health/organ-health. So a clean segment P&L is n/a — not disclosed. What the filings do give:
- Revenue by type:
| FY | Product rev | Licensing/other | Total | YoY |
|---|---|---|---|---|
| 2023 | $1,068.5M | $14.0M | $1,082.6M | — |
| 2024 | $1,685.1M | $11.8M | $1,696.9M | +56.7% |
| 2025 | $2,295.8M | $10.3M | $2,306.1M | +35.9% |
Product is ~99.5% of revenue; licensing (Constellation) is shrinking in absolute terms (-13% in FY2025) — Natera is not a software-margin story, it's a lab-services story.
- Volume mix (the real segment proxy): total tests processed 2.50M (2023) → 3.06M (2024) → 3.53M (2025). Oncology units 528.2k (2024) → 800.8k (2025), +51.6% — Signatera is the accelerant, growing roughly 1.5x the company average. In Q1 2026, oncology units 258.9k vs 167.7k (+54.4% YoY) while total processed hit ~1.01M in a single quarter for the first time.
- Geography: ~98% US, ~2% international ($41.8M intl in FY2025). Essentially a domestic story; international is a rounding error and an untapped option.
Trend + cause: decelerating percentage growth (56.7% → 35.9%) on a bigger base, but accelerating absolute dollars (+$614M in FY2024, +$609M in FY2025) and an accelerating oncology mix-shift that is raising blended ASP (management cites "average selling price improvements" alongside volume in every period).
Phase B — Measure performance
Lens 5 · Earnings Result (Q1 2026, reported 2026-05-07)
The print:
- Total revenue $696.6M, +38.8% YoY ($501.8M PY). Product $693.9M (+38.8%); licensing $2.8M. This beat and management raised FY2026 guidance by ~$120M at the midpoint (from $2.62-2.70B to $2.74-2.82B, GM 64-66%).
- Gross margin 64.7% ($450.8M gross profit) vs 63.1% PY — modest expansion.
- Operating loss $(93.5)M (vs $(79.2)M PY) — loss widened in dollars because opex outran revenue: R&D $210.7M (+63.2%) and SG&A $327.9M (+22.9%). R&D is scaling hard (Foresight integration + trial spend).
- Net loss $(85.1)M, EPS $(0.60) vs $(0.50) PY. The print's EPS loss slightly beat consensus.
- The tell — SBC: stock-based comp was $95.1M this quarter alone — larger than the entire operating loss and larger than the net loss. Natera is cash-generative but GAAP-unprofitable purely because of equity dilution (see Lens 10/11).
- Cash flow: operating cash flow +$40.2M (vs +$44.5M PY) despite a $121M AR build (timing — accrued comp + AR seasonality). Capex $22.1M. FCF roughly +$18M for the quarter.
- Balance sheet: $1.09B cash (incl. $150M restricted as UBS collateral), only $80.3M drawn on the UBS credit line (the sole debt), total assets $2.61B, equity $1.77B. Net-cash, effectively unlevered.
- Market reaction: shares rose ~2.2% to ~$216 after-hours — a "beat-and-raise priced-in" reaction, not a gap.
Unusual vs. own history: the $121M AR outflow is large but explained by accrued-compensation timing; nothing smells like a recognition problem. The standout is the R&D step-up (+63%) — management is plowing the Signatera cash engine back into pipeline + Foresight, which is the right call but suppresses near-term operating leverage.
Lens 6 · Earnings Calls (sentiment trend)
No transcripts on the shelf (transcripts=0), so ``. Tone across the last several quarters has been consistently bullish and volume-led: Q4 2025 ~$666M revenue / ~40% growth with "Signatera volumes exceeded consensus, prompting management to raise guidance"; Q1 2026 "revenue jumps 39%, guidance raised". Recurring management themes: oncology/Signatera momentum, new Medicare indications, ASP improvement, gross-margin expansion toward the mid-60s, and pipeline readouts (ALTAIR/SINERGY). One nuance: a 2026 Q1 transcript headline flagged "mixed results; stock drops" intraday — the chew is whether GAAP losses + rising R&D deserve a ~13x sales multiple, even as the top line compounds. What management has effectively stopped emphasising: a hard breakeven date — and analysts have noticed (Lens 11).
Lens 7 · Comps
Molecular-diagnostics / liquid-biopsy peer set. Multiples are ``, as-of dates noted; NTRA EV/Sales is the standout.
| Company | Ticker | Mkt cap | EV/Sales | Note |
|---|
| Natera | NTRA | $33.1B (2026-06-20) | 12.9x (P/S fwd 11.5x) | |
| Guardant Health | GH | ~$13.1B (2026-02) | ~11.4x (2026-05) | Closest MRD peer (Reveal); also Natera's courtroom adversary |
| Exact Sciences | EXAS | ~$20B → acquired by Abbott | ~6.75x | Delisted 2026-03-23 (ABT acquisition) — major consolidation signal |
| Veracyte | VCYT | ~$3.7B (2026-05) | ~7.6x | Genomic classifiers |
| CareDx | CDNA | ~$1.15B (2026-04) | ~2.5x | Transplant (Natera's Prospera rival + litigation foe) |
P/E, dividend yield, 5-yr avg ROE: n/a — none of these names is GAAP-profitable on a normalized basis; NTRA pays no dividend and ROE is negative (accumulated deficit $2.9B). A P/E table here would be fabrication.
Read: Natera trades at the top of the peer range on EV/Sales (~13x), a premium to Guardant (~11x) and ~2x Exact/Veracyte — justified by the highest growth (+39%) and the MRD-leadership narrative, but it prices in years of flawless execution. The Abbott/Exact deal at ~6.75x is the uncomfortable comp: a profitable strategic acquirer valued the #1 colon-cancer screening franchise at roughly half Natera's sales multiple.
Lens 8 · Stock-Price Catalysts (>5% moves, last ~5 yrs)
Pattern is reimbursement + short-seller + litigation + trial-readout driven, far more than quarterly EPS:
- Mar 2022 — Hindenburg short report: "pioneers in deceptive medical billing." Stock fell ~33% in a day, ~48% peak-to-trough, to ~$36.80. The single biggest move in the name's history — and the genesis of the securities class action (Lens 10).
- Medicare LCD expansions (CRC → bladder → breast → ovarian → lung → IO monitoring, 2021-2026): each coverage win is a step-up catalyst.
- Trial readouts: ALTAIR (CRC, ASCO GI), CALGB/SWOG 80702 (successful Phase III), SINERGY (head & neck, met endpoint) — de-risking the MRD-guided-treatment thesis.
- Guardant $292.5M verdict (Nov 2024) and its July 2025 upholding — litigation overhang catalysts.
- 2026 melt-up: +38% over 52 weeks to ~$231; RBC resumed at Outperform (2026-06-11).
What the market actually reacts to: (1) Medicare/payer coverage decisions, (2) Signatera volume vs. consensus, (3) short-seller/legal headlines, (4) major trial data. Not GAAP EPS — the loss is understood as SBC-driven.
Phase C — Judge people & books
Lens 9 · Management
- Steve Chapman — CEO (since Jan 2019), President, Director. Joined Natera 2010; rose VP Sales → COO → CEO. Prior: GE Healthcare Life Sciences (head of precision diagnostics) + GE Ventures (2012-2016). UCLA micro/immuno/molecular-genetics. Track record: presided over the revenue ramp from a few hundred million to $2.3B (FY2025) and the Signatera commercialization + reimbursement build — a genuine, quantified operating achievement. Deep reimbursement expertise is exactly the scarce skill this business needs.
- Matthew Rabinowitz, Ph.D. — Co-founder, Executive Chairman (CEO 2005-2019). Built "the highest-volume clinical genetic test in US history" (Panorama) and the Signatera platform; 2x WEF Technology Pioneer, 3x Edison Awards. Founder-led at the board level — strong technical/visionary anchor.
- Michael Brophy — CFO (signs the filings).
- Skin in the game / insider selling:
insider-transactions.csv absent, but the 10-Q discloses 10b5-1 plans: Chapman modified a plan for up to 180,643 shares (sales Jun-2026→Mar-2028, much performance-gated); Rabinowitz adopted a plan for up to 100,000 shares (Jun-Dec 2026). Routine, pre-arranged, partly performance-conditioned — not a red flag, but worth tracking given the run-up.
- Capital allocation: historically reinvest-and-dilute — fund the cash gap with equity (SBC + issuance), no buybacks, no dividend. The Foresight deal ($424.5M, all-stock) and Invitae asset purchase show an M&A appetite funded with richly-valued equity — smart while the stock is at 13x sales, dilutive if it de-rates. ROIC is structurally negative (still pre-GAAP-profit); the bet is that today's R&D/coverage spend compounds into tomorrow's operating leverage.
- Archetype: founder-anchored + professional-operator CEO — a healthy pairing for a scaling commercial diagnostics company. Related-party flag: the MyOme investment — exec chairman Rabinowitz is MyOme's chairman/founder/interim-CEO and a ~19.4% holder; co-founder Sheena and CLO Daniel Rabinowitz are also holders; lead independent director Roelof Botha (Sequoia) is connected via Sequoia's MyOme stake. Natera has put $16.7M of capital + warrants worth $20.0M into MyOme. Disclosed and not large, but it is a genuine related-party web around a director-controlled private company — monitor it.
Lens 10 · Forensic Red Flags
Accounting risk map (every figure ):
- Revenue recognition — the #1 area to watch. Natera books revenue at estimated variable consideration (expected cash collections, constrained for refunds) under ASC 606 — i.e., management estimates what insurers will actually pay and recognizes that, before cash arrives. This is inherently judgmental and was the crux of the Hindenburg billing critique. Mitigants: no single customer >10%; the portfolio/expected-value method is standard for the industry; auditor (per 10-K) issued a clean opinion. But a downward reimbursement revision would hit reported revenue directly.
- SBC flatters nothing on GAAP, but masks cash reality. FY2025 SBC $354.4M (Q1 2026 alone $95.1M). The entire GAAP net loss ($208.2M FY2025; $85.1M Q1) is smaller than annual SBC — Natera is FCF-positive but GAAP-loss-making solely because of equity dilution. Share count rose from ~132.6M (Dec-2024) to 142.7M (Mar-2026) — ~7-8%/yr dilution. Non-GAAP/adjusted metrics will look dramatically better than GAAP; insist on per-share, dilution-adjusted analysis.
- One-time tax benefit flatters FY2025. FY2025 net loss of $208.2M includes a $59.9M income-tax benefit — driven by the Foresight deferred-tax-liability recognition releasing valuation allowance. Strip it and the operating loss is $309.9M — the underlying loss is worse than the headline.
- Goodwill/intangibles from Foresight. $141M goodwill + $335.3M developed-technology intangible booked at a 12% discount rate on "forecasted clinical revenue". Aggressive growth assumptions underpin the carrying value; an MRD slowdown could trigger impairment. Contingent consideration up to $175M (fair-valued $118-125M) is re-marked through SG&A every quarter — a $7.2M markup hit SG&A in Q1 2026, adding non-operating noise to opex.
- AR vs. revenue. AR jumped (a $121M Q1 outflow) — partly seasonal/accrual timing, but receivables in a reimbursement-estimate business always warrant watching for collection shortfalls vs. booked estimates. No incremental credit-loss reserve is held against insurance/patient AR (the risk is said to be embedded in the ASP estimate).
- Leases: $204.5M future minimum lease payments, $159.8M lease liability, 7.2-yr WAL — sizable but ordinary for a multi-lab footprint.
Regulatory findings (required sub-section):
- SEC Litigation Releases / AAERs: None. EDGAR EFTS returned 0 LR and 0 AAER for "Natera" since 2021-06-20.
- 10-K Item 3 / Note 10 Legal Proceedings — material and extensive:
- Guardant Health false-advertising verdict — the big one. Nov 2024 jury found Natera liable; damages $292.5M (incl. $175.5M punitive, $75M corrective advertising, $42M disgorgement) over 2021 ads comparing Signatera to Guardant Reveal. In July 2025 the court largely upheld the verdict; Natera plans to appeal to the 9th Circuit. Final judgment not yet entered. This is a real, large, partially-adjudicated contingent liability.
- Securities class action (10b-5): filed W.D. Texas Apr-2022 (post-Hindenburg), alleging false/misleading statements about products/operations. Motion to dismiss granted-in-part/denied-in-part; the class has been certified — it is live and advancing. Plus two shareholder derivative suits (Oct-2023, Jan-2024).
- Patient/consumer class actions: multiple over billing practices and Panorama marketing and PGT-A — several settled/in-settlement, some dismissed-without-prejudice then re-amended.
- IP litigation web (Natera usually the aggressor): wins — NeoGenomics RaDaR enjoined/withdrawn; ArcherDX/Invitae 30% ongoing royalty + ~$1.23M supplemental damages (Apr 2026); losses — several Natera patents invalidated (CareDx Patent Cases, Ravgen $57M against Natera on non-willful infringement with judgment not yet entered). LabCorp/Invitae matter settled Sep-2025.
- Aggregate legal accrual: ~$33.0M (Mar-2026), and management states it cannot estimate the range of loss above accruals for the major matters. The $292.5M Guardant exposure is not fully reserved.
- Non-SEC enforcement (web): the 2022 Hindenburg report alleged deceptive billing/possible insurance-fraud patterns; Natera disputed it. No disclosed FTC/DOJ/CMS enforcement settlement surfaced in search, but the consumer-billing class actions are the civil echo of those allegations.
Net forensic read: the books are clean enough (no SEC actions, clean audit, standard-but-judgmental revenue method) — but the litigation tail is unusually heavy (a $292.5M verdict on appeal + a certified securities class action), the GAAP loss is cosmetically worse than the SBC-masked cash reality, and a one-time tax benefit flattered FY2025. Quality-of-earnings: cash-positive and real, but read non-GAAP claims with the dilution in hand.
Phase D — Project & stress-test
Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028)
Built bottom-up from the latest actuals + raised guidance. Revenue is well-anchored; EPS is the contested variable.
Revenue:
- FY2026: ~$2.78B — company guide $2.74-2.82B; consensus $2.77B (18 analysts). ≈ +20% YoY. ``
- FY2027: ~$3.3B — consensus implies similar (analysts model ~20% 3-yr revenue CAGR ).
- FY2028: ~$3.9-4.0B.
EPS — the honest part: n/a as a positive number. Natera is GAAP-loss-making and consensus does NOT model breakeven in the forecast horizon. The 18-analyst consensus is FY2026 EPS ≈ $(1.69) and FY2027 ≈ a ~$8.25M net loss (essentially flat-to-slightly-negative) — and "analysts no longer expect the company to break even during the foreseeable future". The bridge to cash profitability already exists (TTM FCF +$104.5M ); the bridge to GAAP profitability is gated on SBC moderating relative to a growing revenue base.
- Base case: revenue compounds high-teens/low-20s; gross margin holds 64-66%; FCF stays positive and grows; GAAP net loss persists (~$(1.50)-$(1.70) EPS in FY2026) as R&D + SBC stay elevated; the stock is driven by revenue/coverage, not earnings.
- Bull case: oncology mix-shift + new Medicare indications push ASP and revenue to the high end ($2.82B+ FY2026, ~$3.5B FY2027); operating leverage finally appears as SG&A growth (+23%) lags revenue (+39%); FCF inflects toward $250M+; the market re-rates the path to GAAP profit.
- Bear case: a payer reimbursement cut (microdeletions precedent), a competitive MRD share-loss to Guardant/Tempus, or the Guardant $292.5M judgment crystallizing — revenue decelerates to ~10-12%, the 13x multiple compresses toward Exact's 6.75x, and the equity halves on multiple alone.
Brier forecast (logged conceptually; not committed via forecast.ts in --watchlist): "NTRA FY2027 GAAP EPS ≥ $0.00 (breakeven)" — p ≈ 0.20 (consensus says no; bet against breakeven). The more useful tracked binary: "NTRA FY2026 revenue ≥ $2.80B" — p ≈ 0.55 (top half of guide, given the beat-and-raise cadence).
Lens 12 · Bull vs Bear
Bull case. Natera owns the leading tumor-informed MRD franchise in a market estimated at $20B+ TAM growing ~30%/yr and <10% penetrated. Signatera is compounding ~50%+ with the broadest Medicare coverage in MRD (6 cancer types + IO monitoring) and ADLT pricing of $3,500-3,920 — a reimbursement moat rivals must re-clear indication-by-indication. The platform throws off positive free cash flow on a net-cash balance sheet ($847M), so it funds its own pipeline. Trial readouts (ALTAIR/SINERGY/CALGB-SWOG) are moving MRD from "monitoring" to "treatment-guiding," which expands the billable population. Optionality: women's-health/organ-health are mature cash cows subsidizing the oncology land-grab; international is untapped; the Abbott/Exact deal proves strategics will pay up for category leaders — Natera is the most obvious next consolidation prize.
Bear case (permanent-impairment risks). (1) Reimbursement is the whole moat and it cuts both ways — Natera itself flags that going in-network lowers realized price, and Medicare has previously declined coverage (microdeletions); a single adverse LCD or a CMS ADLT re-pricing could reset the model. (2) The multiple is the risk. ~13x sales for a GAAP-unprofitable company with no consensus breakeven in sight prices perfection; the Abbott/Exact comp at ~6.75x is a ~2x de-rate waiting to happen if growth slips. (3) Litigation tail — the $292.5M Guardant verdict (only ~$33M reserved) plus a certified securities class action are real, large, and only partly adjudicated. Pre-mortem (18 months out, thesis broke): Medicare trims MRD reimbursement OR a competitor (Guardant Reveal, Tempus, NeoGenomics RaDaR-ST) clears the same indications and compresses ASP; oncology growth decelerates from 50% to 25%; the 9th Circuit affirms Guardant; the stock re-rates from 13x to 7x sales and halves — with the business still growing. Contrarian view the market refuses to see: the bull and bear are both about the top line — almost nobody is underwriting the dilution drag (7-8%/yr share growth, $354M/yr SBC) that means even a doubling of revenue may not produce the GAAP earnings the multiple implicitly demands.
Multiple assessment: too high on any earnings-based frame, defensible only on growth-adjusted EV/Sales — and only if ~20% growth holds for 3+ years. Asymmetry skews to the downside from here.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case. Where revenue is concentrated: in payer reimbursement policy — ~15% of revenue is traditional Medicare, and the recognized number is an estimate of insurer collections, not contracted cash. What breaks it: (a) a CMS or large-commercial coverage/price reset — the microdeletions denial is the precedent that it can happen; (b) Natera books revenue on expected-value estimates that the same short thesis (Hindenburg 2022) called "deceptive billing" — a certified securities class action is now litigating exactly that. The moat is weaker than bulls think because it's rented twice: the sequencing is single-source Illumina (no cost moat), and the reimbursement is granted by payers who are actively trying to curb molecular-test spend. Most dangerous competitor bulls underestimate: not Guardant (the courtroom rival) but Tempus AI (data-scale + AI narrative) and a post-Abbott Exact Sciences — Abbott's distribution + balance sheet behind a colon-cancer franchise could subsidize MRD entry and crush ASP. Worst capital-allocation/governance items: the MyOme related-party web (exec chairman controls the counterparty), $354M/yr SBC diluting holders ~8%/yr, and an all-stock M&A habit that only works while the stock is expensive. Assumptions that must hold for today's price: ~20% revenue CAGR for 3+ years, no reimbursement cut, no large litigation cash-out, and eventual operating leverage despite a +63% R&D quarter. If growth disappoints 20-30% (say FY2026 lands $2.4B not $2.8B): the 13x multiple is indefensible, mean-reversion toward 6-7x sales halves-to-thirds the equity. Single permanent-impairment scenario: a standard-of-care MRD reimbursement downgrade (CMS narrows LCDs or cuts the ADLT rate) — moderately plausible given payer cost-pressure, and it would hit both revenue and the multiple simultaneously.
Lens 14 · Management Questions (ordered by information value)
- What is your realistic GAAP-breakeven year, and what SBC-as-%-of-revenue trajectory gets you there — given consensus now models no breakeven in the forecast horizon?
- On the $292.5M Guardant verdict: what is your probability-weighted cash exposure post-appeal, why is only ~$33M accrued, and what's the worst-case 9th-Circuit outcome?
- Signatera ASP — what was blended realized price per oncology unit in FY2025, and how much of revenue growth is volume vs. price as ADLT pricing matures?
- What is your dependence on Illumina post-11th-amendment — pricing terms, alternative sequencers qualified (Element/Ultima), and the COGS sensitivity to a reagent price change?
- Which Medicare LCD is most at risk of narrowing or re-pricing, and what % of revenue rides on the single most-exposed coverage decision?
- Define the oncology TAM you can actually bill (covered indications × realized ASP × penetration) vs. the headline "$20B MRD market."
- Foresight developed-technology intangible ($335M at a 12% discount rate): what clinical-revenue ramp underpins it, and what would trigger impairment?
- MyOme — given the executive-chairman control and Sequoia ties, why is this the right use of Natera capital, and what governance ring-fence protects minority holders?
- How do you defend MRD share against a post-Abbott Exact Sciences and against Tempus/Guardant on price as the field commoditizes?
- Capital allocation: at ~13x sales, is all-stock M&A still your preferred currency, and at what valuation would you switch to buybacks?
- International is ~2% of revenue — is that a strategic choice or a capability gap, and what's the 5-year mix target?
- The certified securities class action: what is the financial-statement risk, and what changed in disclosure controls since 2022?
- Women's-health/organ-health — are these managed-for-cash to fund oncology, and what's the reinvestment split?
- With R&D +63% YoY, what specific programs is that funding and what ROIC hurdle do you apply to trial spend?
- What single operating metric should investors track to know the operating-leverage inflection has actually begun?